Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

2.2K

Heterozygous Chorein Deficiency in Probable Tau-negative Early-onset Alzheimer Disease

Maciej J Lazarczyk1, Sven Haller, Stefania Gimelli

  • 1Departments of *Mental Health and Psychiatry, Division of General Psychiatry †Imaging and Medical Informatics, University Hospitals of Geneva, Faculty of Medicine of the University of Geneva ‡Department of Medical Genetic and Laboratories, University Hospitals of Geneva, Geneva, Switzerland.

Alzheimer Disease and Associated Disorders
|January 31, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

19.1K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

28.4K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K